Company profile: Tolmar
1.1 - Company Overview
Company description
- Provider of pharmaceutical research, development, manufacturing and commercial operations, delivering proprietary and generic products in dermatology, oncology, and dental therapeutics, including ELIGARD (leuprolide acetate for prostate cancer), Fensolvi (leuprolide acetate for central precocious puberty), and topical dermatology generics—ointments, creams, gels, and lotions.
Products and services
- Fensolvi: A pediatric-indicated leuprolide acetate injectable suspension used for treating central precocious puberty in children, engineered for central precocious puberty care
- ELIGARD: An oncology-indicated leuprolide acetate injectable suspension developed and produced by Tolmar, used in treating prostate cancer via injectable suspension format
- Specialty Generics: Dermatology-focused topical generics that Tolmar develops and produces, including ointments, creams, gels, and lotions for topical dermatological applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tolmar
Antibe Therapeutics
HQ: Canada
Website
- Description: Provider of novel anti-inflammatory drugs that improve existing, proven therapies, targeting diseases characterized by inflammation, pain, and vascular dysfunction. Offers a proprietary hydrogen sulfide platform; pipeline includes Otenaproxesul for acute pain with demonstrated gastrointestinal safety and efficacy in chronic pain, ATB-352 for specialized pain, and a program for mild-to-moderate inflammatory bowel disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antibe Therapeutics company profile →
Cyclenium Pharma
HQ: Canada
Website
- Description: Provider of next-generation macrocyclic drug discovery technology (CMRT) and the QUEST library of small-molecule macrocycles to identify novel therapeutics for difficult disease targets. Offers collaborative drug discovery, out-licensing of advanced leads (e.g., anti-flaviviral agents, opioid receptor agonists), and in-licensing opportunities in oncology and anti-infectives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclenium Pharma company profile →
Redwood Bioscience
HQ: United States
Website
- Description: Provider of precision protein-chemical engineering to develop optimized, novel biotherapeutics using site-specific modification technology to create homogenous biologic-synthetic conjugates; offering microscale perfusion-based cultivation for Pichia pastoris, E. coli recombinant proteins, CagA diagnostic proteins, and KRAS G12D recombinant protein vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Redwood Bioscience company profile →
Axys Pharmaceuticals
HQ: United States
Website
- Description: Provider of discovery, design, and development services for therapeutic small molecules addressing significant markets with major unmet medical needs; collaborates with large pharmaceutical companies to discover therapeutics for chronic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axys Pharmaceuticals company profile →
Pinteon Therapeutics
HQ: United States
Website
- Description: Provider of a monoclonal antibody therapeutic, PNT001, targeting cis-pT231 tau to reduce neurodegeneration and cognitive impairment in traumatic brain injury, chronic traumatic encephalopathy, Alzheimer's disease, and progressive supranuclear palsy; advancing clinical studies of this novel antibody.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pinteon Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tolmar
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tolmar
2.2 - Growth funds investing in similar companies to Tolmar
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tolmar
4.2 - Public trading comparable groups for Tolmar
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →